Curcumin attenuates LPS-induced inflammation in RAW 264.7 cells: A multifaceted study integrating network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation
Curcumin hemmt LPS-induzierte Entzündung in RAW 264.7-Zellen: eine multifaktorielle Studie mit Netzwerkpharmakologie, molekularem Docking, Molekulardynamik und experimenteller Validierung
PLOS One · 23.10.2025 · 20 (10) · e0335139
DOI: 10.1371/journal.pone.0335139 ↗Auf einen Blick
Curcumin wurde in einem integrierten Ansatz gegen LPS-induzierte Entzündung in RAW 264.7-Zellen untersucht. Es senkte NO sowie die mRNA-Expression von IL-1β, IL-6 und TNF.
Fragestellung
Welche molekularen Mechanismen liegen den antiinflammatorischen Effekten von Curcumin zugrunde?
Methode
Netzwerkpharmakologie, molekulares Docking, Molekulardynamik und in vitro Validierung in LPS-induzierten RAW 264.7-Zellen.
Ergebnisse
135 potenzielle Targets und mehrere Signalwege wurden identifiziert. Curcumin band an IL-6, TNF, IL-1β, AKT1 und STAT3; die Komplexe blieben über 100 ns stabil. In vitro wurden NO sowie IL-1β, IL-6 und TNF reduziert.
Einschränkungen
Weitere In-vivo-Studien sind notwendig.
Schlussfolgerung der Autor:innen
Die Studie liefert ein umfassendes Verständnis der antiinflammatorischen Mechanismen von Curcumin und zeigt sein Potenzial als therapeutischer Wirkstoff bei Entzündungserkrankungen.
Kernaussagen
- 135 potenzielle Targets und mehrere Entzündungssignalwege
- Reduktion von NO sowie IL-1β, IL-6 und TNF
- Optimale Effekte bei 125 μg/mL in RAW 264.7-Zellen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 23.10.2025. Verfasst von Xiaojing Gong und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Qingdao Binhai University, Qingdao, Shandong Province, P. R. China. Hauptthemen laut MEDLINE: Curcumin, Lipopolysaccharides, Inflammation, Anti-Inflammatory Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Shandong Medical and Health Science and Technology Development Plan Project.
Abstract (Originalsprache)
Background
Inflammation is a critical immune response that protects the body from infections and injuries. However, chronic inflammation can lead to diseases such as cancer. Curcumin, a bioactive compound extracted from Curcuma longa , has been widely studied for its anti-inflammatory properties. Despite extensive research, the comprehensive molecular mechanisms underlying curcumin’s anti-inflammatory effects, particularly its multi-target regulatory network, remain incompletely understood. This study aims to elucidate these mechanisms using an integrated approach combining network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experimental validation.
Methods
We utilized network pharmacology to identify potential targets and pathways involved in curcumin’s anti-inflammatory effects. Molecular docking and dynamics simulation were conducted to evaluate the binding affinity and stability of curcumin with key inflammatory targets. The anti-inflammatory effects of curcumin were further validated in vitro using LPS-induced RAW 264.7 cells. Cell viability, NO content, and mRNA expression levels of pro-inflammatory cytokines ( IL-1β , IL-6, and TNF ) were assessed.
Results
Network pharmacology identified 135 potential targets for curcumin’s anti-inflammatory effects, with key pathways including TNF, HIF-1, PI3K-Akt, JAK-STAT, and MAPK signaling pathways. Molecular docking revealed strong binding affinities of curcumin with core targets such as IL-6, TNF, IL-1β, AKT1, and STAT3, with binding energies ranging from −6.2 to −7.5 kcal/mol. Molecular dynamics simulations demonstrated the stability of these complexes over a 100-nanosecond period. In vitro experiments showed that curcumin significantly reduced NO production and mRNA expression of IL-1β , IL-6, and TNF in LPS-induced RAW 264.7 cells, with optimal effects observed at a concentration of 125 μg/mL.
Conclusion
Our study provides a comprehensive understanding of curcumin’s anti-inflammatory mechanisms through an integrated approach. The findings highlight curcumin’s potential as a therapeutic agent for inflammatory diseases. However, further in vivo studies are necessary to fully elucidate its therapeutic efficacy and mechanisms of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Qingdao Binhai University, Qingdao, Shandong Province, P. R. China.
ORCID-Profile: Jingjing Kong
Förderung
- Natural Science Foundation of Shandong Province
- Shandong Medical and Health Science and Technology Development Plan Project
Zitieren
APA
Gong, X., Xue, D., Meng, H., Xie, B., Zhao, L., Zang, C., & Kong, J. (2025). Curcumin attenuates LPS-induced inflammation in RAW 264.7 cells: A multifaceted study integrating network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation. PLOS One, 20(10), e0335139. https://doi.org/10.1371/journal.pone.0335139
Vancouver
Gong X, Xue D, Meng H, Xie B, Zhao L, Zang C, et al. Curcumin attenuates LPS-induced inflammation in RAW 264.7 cells: A multifaceted study integrating network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation. PLOS One. 2025;20(10):e0335139. doi:10.1371/journal.pone.0335139
BibTeX
@article{Gong2025,
author = {Gong, Xiaojing and Xue, Dingshan and Meng, Hongyan and Xie, Bing and Zhao, Lihua and Zang, Chuanhui and Kong, Jingjing},
title = {Curcumin attenuates LPS-induced inflammation in RAW 264.7 cells: A multifaceted study integrating network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0335139},
doi = {10.1371/journal.pone.0335139}
}
EUVIMED